+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malaria Vaccine Market by Vaccine Type, Distribution Channel, End User, Route of Administration, Age Group, Dosage Schedule - Global Forecast to 2030- Product Image
Malaria Vaccine Market by Vaccine Type, Distribution Channel, End User, Route of Administration, Age Group, Dosage Schedule - Global Forecast to 2030- Product Image
Sale

Malaria Vaccine Market by Vaccine Type, Distribution Channel, End User, Route of Administration, Age Group, Dosage Schedule - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5313766
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Malaria Vaccine Market grew from USD 80.88 million in 2024 to USD 102.59 million in 2025. It is expected to continue growing at a CAGR of 25.86%, reaching USD 321.53 million by 2030.

Emergence of a New Era in Malaria Prevention

Malaria continues to impose a significant health burden across endemic regions, claiming hundreds of thousands of lives annually and placing immense strain on healthcare systems. In recent years, breakthroughs in vaccine technology have ignited new hope for large-scale disease prevention. As the industry pivots from traditional immunization approaches toward next-generation platforms, stakeholders across public health agencies, pharmaceutical companies and global funding bodies are recalibrating priorities.

This executive summary synthesizes the key developments in malaria vaccine research and deployment. It highlights the historical context leading to contemporary vaccine candidates, the pivotal role of advanced platforms in shaping clinical outcomes and the emerging dynamics influencing market access. By framing the current landscape in light of scientific innovation and shifting regulatory frameworks, this introduction lays the groundwork for understanding how strategic decisions today will determine the trajectory of global malaria eradication efforts.

Shifting Dynamics Reshaping Vaccine Development

Researchers and industry pioneers have catalyzed transformative shifts in the malaria vaccine landscape by embracing innovative modalities and forging cross-sector collaborations. The advent of mRNA platforms has accelerated antigen design cycles, enabling rapid iteration and optimization of immunogenic constructs. Simultaneously, viral vector technologies have matured, offering robust cellular responses that complement humoral immunity. This convergence of platforms has sparked a paradigm shift in candidate prioritization, urging developers to weigh speed to clinic against long-term durability of protection.

On the regulatory front, agencies have instituted adaptive review pathways, expediting approval for breakthrough designations while preserving stringent safety evaluations. Funding consortia have restructured grant mechanisms to incentivize open-source data sharing, fostering transparency in trial outcomes and reducing redundancies. At the same time, public-private partnerships have expanded the geographic breadth of clinical sites, enhancing the diversity of participant cohorts and generating more representative efficacy data. Together, these strategic realignments are redefining what a successful malaria vaccine portfolio looks like and setting the stage for accelerated global deployment.

Unpacking the Effects of US Tariffs on Global Supplies

In 2025, the imposition of new United States tariffs on key vaccine inputs introduced complexity into an already intricate global supply chain. Raw materials such as lipid nanoparticles and specialized adjuvants encountered elevated import costs, prompting manufacturers to re-evaluate supplier contracts and production footprints. While some organizations absorbed these additional expenses through operational efficiencies, others shifted procurement toward alternative sources in Asia and Europe to mitigate financial impact.

The tariff adjustments also reshuffled logistics flows, as companies explored transshipment hubs and free trade zones to circumvent direct duties. Despite short-term cost fluctuations, these measures ultimately strengthened supply chain resilience by diversifying sourcing networks. Moreover, tariff-induced pressure galvanized stakeholders to negotiate longer- term agreements with raw-material providers, fostering stability in pricing structures. Consequently, the market has emerged from this tariff cycle with more transparent cost models and enhanced collaboration across regions to safeguard against future policy shifts.

Diverse Market Segments Driving Targeted Strategies

A nuanced understanding of market segmentation underpins targeted vaccine development and commercialization strategies. When viewed through the lens of vaccine type, distinctions among conjugate, live attenuated, subunit and viral vector platforms reveal divergent clinical and manufacturing profiles. Within the mRNA category, conventional constructs compete with self-amplifying designs that promise lower dose requirements, while viral vector efforts split between adenovirus-based and MVA-based approaches that balance immunogenic potency with established safety records.

Distribution channels offer another layer of insight, with hospital pharmacies-both private and public-serving as critical nodes for initial rollout in high-burden settings, complemented by the growing footprint of online pharmacies and the broad reach of chain and independent retail outlets. End users likewise span a spectrum from non-governmental organizations coordinating community outreach to private clinics tailoring vaccination services, alongside expansive public immunization programs managed at local and national levels.

Route of administration segments further refine product positioning, as developers optimize formulations for intramuscular injections, oral dosing and subcutaneous delivery to align with patient preferences and operational constraints. Age group categorization-encompassing adolescent and adult populations, school-age and preschool children, and infants-drives dosage formulation and trial design, while distinct single-dose, two-dose and three-dose schedules inform adherence strategies and logistics planning. This multilayered segmentation framework enables stakeholders to prioritize resources and customize engagement models for maximum impact.

Regional Variations Shaping Market Adoption

Regional nuances profoundly influence both the development and diffusion of malaria vaccines. In the Americas, established public health infrastructures and growing private-sector capacity bolster clinical trial pipelines and support vaccine introductions in high-risk areas of Central and South America. Investments in cold-chain expansion and digital immunization registries have further catalyzed uptake.

Within Europe, Middle East & Africa, a dual dynamic unfolds: European stakeholders provide crucial R&D funding and technical expertise, while African nations grapple with implementation challenges amid varying healthcare budgets. Collaborative initiatives across these zones have prioritized technology transfer and local manufacturing to reduce dependence on external supply. Political commitment in key countries has translated into accelerated regulatory harmonization and increased procurement volumes under pooled procurement mechanisms.

In the Asia-Pacific region, rapid economic growth in South Asia and Southeast Asia drives rising public health expenditures, enabling broader vaccine coverage. National roll-out campaigns leverage existing immunization platforms to integrate malaria vaccines, while expanding private healthcare networks and e-health platforms facilitate last-mile delivery. These regional distinctions underscore the necessity of context-specific strategies, from policy alignment and financing to logistics optimization and community engagement.

Key Market Players and Their Strategic Positions

A handful of global biopharmaceutical leaders and agile innovators are steering the competitive landscape. Companies with robust mRNA capabilities have pivoted from traditional vaccine portfolios to pioneer novel malaria constructs, drawing on clinical expertise gained during recent pandemic responses. Concurrently, established vaccine manufacturers have fortified their subunit and conjugate platforms through strategic collaborations, licensing agreements and targeted investments in manufacturing scale-up.

Emerging players operating regional manufacturing hubs have capitalized on local partnerships to secure advance purchase commitments from public immunization programs, positioning themselves as key suppliers in underserved markets. Some organizations are differentiating through proprietary adjuvant technologies that enhance antigen presentation, while others highlight their cold-chain-free formulations to reduce logistical burdens. Across the spectrum, successful companies blend scientific rigor with flattened decision-making structures, allowing them to respond rapidly to trial outcomes and policy shifts. The interplay of global R&D prowess and regional execution excellence will define market leadership in the coming years.

Strategic Recommendations for Industry Decision Makers

Industry leaders should accelerate investment in modular vaccine platforms that can adapt to antigenic variations and emergent parasite strains. By prioritizing flexible manufacturing capabilities, organizations can shorten development timelines and mitigate supply disruptions caused by policy changes or raw-material constraints. Simultaneously, establishing strategic partnerships with governments and funding agencies will be critical for securing advanced purchase agreements and co-funding pilot deployment programs.

Diversifying distribution channels through integration with digital health platforms and mobile immunization units will expand reach into remote communities and improve real-time tracking of coverage rates. Tailoring communication strategies for distinct demographic cohorts-drawing on human-centered design principles-can enhance vaccine acceptance and adherence, particularly among parents of young children and adolescent populations. Finally, leveraging real-world evidence generated through post-launch surveillance will inform iterative improvements in dosage schedules and administration routes, thereby sustaining long-term protection and reinforcing stakeholder confidence.

Rigorous Methodology Underpinning Our Analysis

This analysis draws on a rigorous methodology that integrates primary and secondary research, expert interviews and quantitative data synthesis. Primary insights were collected through structured discussions with leading scientists, regulatory authorities and supply chain specialists, ensuring a well-rounded perspective on clinical, policy and operational dynamics. Secondary materials-including peer-reviewed literature, patent filings and publicly available trial registries-were systematically reviewed to validate emerging trends and corroborate proprietary information.

Quantitative analysis applied statistical techniques to assess correlations between technological variables, policy shifts and regional adoption patterns. Data triangulation across multiple sources enhanced the reliability of findings, while scenario mapping exercises explored potential market trajectories under varying tariff and funding environments. This comprehensive approach ensures that the conclusions and recommendations herein are both evidence-based and grounded in real-world considerations.

Synthesis of Core Insights and Market Characteristics

The current malaria vaccine landscape stands at a pivotal juncture, characterized by rapid technological innovation, evolving regulatory frameworks and shifting supply-chain dynamics. Transformative modalities such as mRNA and viral vectors have expanded the arsenal of candidate vaccines, while new tariff realities have catalyzed more resilient procurement strategies. Detailed segmentation reveals critical pathways for targeting age groups, administration routes and distribution channels, and regional variations highlight the importance of localized execution models.

Market leadership will align with organizations that combine platform agility, robust partnerships and data-driven decision-making. By adhering to the strategic recommendations outlined here-centering on modular manufacturing, diversified channels and evidence-generation-stakeholders can advance toward the shared goal of reducing the global malaria burden. The synthesis of core insights provided in this report offers a definitive roadmap for guiding both investment and operational priorities in the near term and beyond.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Conjugate Vaccine
    • Live Attenuated Vaccine
    • Mrna Vaccine
      • Conventional Mrna
      • Self Amplifying Mrna
    • Subunit Vaccine
    • Viral Vector Vaccine
      • Adenovirus Vector
      • Mva Vector
  • Distribution Channel
    • Hospital Pharmacies
      • Private Hospitals
      • Public Hospitals
    • Online Pharmacies
    • Retail Pharmacies
      • Chain Pharmacies
      • Independent Pharmacies
  • End User
    • Ngos
    • Private Clinics
    • Public Immunization Programs
      • Local Programs
      • National Programs
  • Route Of Administration
    • Intramuscular
    • Oral
    • Subcutaneous
  • Age Group
    • Adolescent & Adult
    • Child
      • Preschool
      • School Age
    • Infant
  • Dosage Schedule
    • Single Dose
    • Three Dose
    • Two Dose
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech International Limited
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novavax, Inc.
  • BioNTech SE
  • Moderna, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Malaria Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. Conjugate Vaccine
8.3. Live Attenuated Vaccine
8.4. Mrna Vaccine
8.4.1. Conventional Mrna
8.4.2. Self Amplifying Mrna
8.5. Subunit Vaccine
8.6. Viral Vector Vaccine
8.6.1. Adenovirus Vector
8.6.2. Mva Vector
9. Malaria Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Private Hospitals
9.2.2. Public Hospitals
9.3. Online Pharmacies
9.4. Retail Pharmacies
9.4.1. Chain Pharmacies
9.4.2. Independent Pharmacies
10. Malaria Vaccine Market, by End User
10.1. Introduction
10.2. Ngos
10.3. Private Clinics
10.4. Public Immunization Programs
10.4.1. Local Programs
10.4.2. National Programs
11. Malaria Vaccine Market, by Route of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Oral
11.4. Subcutaneous
12. Malaria Vaccine Market, by Age Group
12.1. Introduction
12.2. Adolescent & Adult
12.3. Child
12.3.1. Preschool
12.3.2. School Age
12.4. Infant
13. Malaria Vaccine Market, by Dosage Schedule
13.1. Introduction
13.2. Single Dose
13.3. Three Dose
13.4. Two Dose
14. Americas Malaria Vaccine Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Malaria Vaccine Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Malaria Vaccine Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. GlaxoSmithKline plc
17.3.2. Serum Institute of India Pvt. Ltd.
17.3.3. Bharat Biotech International Limited
17.3.4. Sanofi S.A.
17.3.5. Merck & Co., Inc.
17.3.6. Pfizer Inc.
17.3.7. Janssen Pharmaceuticals, Inc.
17.3.8. Novavax, Inc.
17.3.9. BioNTech SE
17.3.10. Moderna, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MALARIA VACCINE MARKET MULTI-CURRENCY
FIGURE 2. MALARIA VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. MALARIA VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES MALARIA VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES MALARIA VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MALARIA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MALARIA VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MALARIA VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES MALARIA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 78. CANADA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 79. CANADA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. CANADA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. CANADA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. CANADA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CANADA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 84. CANADA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. CANADA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 87. CANADA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 89. MEXICO MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 91. MEXICO MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 94. MEXICO MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. MEXICO MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 99. MEXICO MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. GERMANY MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. GERMANY MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. GERMANY MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. GERMANY MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 160. GERMANY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 161. FRANCE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 162. FRANCE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 163. FRANCE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 164. FRANCE MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. FRANCE MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. FRANCE MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 167. FRANCE MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FRANCE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 169. FRANCE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 171. FRANCE MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 172. FRANCE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 185. ITALY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 186. ITALY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 187. ITALY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 188. ITALY MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. ITALY MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 190. ITALY MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 191. ITALY MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. ITALY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 193. ITALY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. ITALY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. ITALY MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 196. ITALY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 197. SPAIN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 198. SPAIN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 199. SPAIN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 200. SPAIN MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SPAIN MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. SPAIN MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 203. SPAIN MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. SPAIN MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 208. SPAIN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 245. DENMARK MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 246. DENMARK MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 247. DENMARK MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. DENMARK MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 250. DENMARK MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. DENMARK MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. DENMARK MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. DENMARK MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. DENMARK MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 256. DENMARK MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 269. QATAR MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 270. QATAR MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 271. QATAR MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 272. QATAR MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. QATAR MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 274. QATAR MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. QATAR MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. QATAR MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 277. QATAR MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. QATAR MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. QATAR MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 280. QATAR MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 281. FINLAND MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 282. FINLAND MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 283. FINLAND MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 284. FINLAND MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. FINLAND MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 286. FINLAND MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 287. FINLAND MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. FINLAND MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. FINLAND MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 291. FINLAND MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 292. FINLAND MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 317. EGYPT MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 318. EGYPT MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 319. EGYPT MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 320. EGYPT MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. EGYPT MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 322. EGYPT MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 323. EGYPT MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. EGYPT MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 325. EGYPT MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. EGYPT MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 327. EGYPT MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 328. EGYPT MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 329. TURKEY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 330. TURKEY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 331. TURKEY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 332. TURKEY MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 333. TURKEY MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 334. TURKEY MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 335. TURKEY MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. TURKEY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 337. TURKEY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 338. TURKEY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 339. TURKEY MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2030 (USD MILLION)
TABLE 340. TURKEY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2030 (USD MILLION)
TABLE 341. ISRAEL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 342. ISRAEL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2030 (USD MILLION)
TABLE 343. ISRAEL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2030 (USD MILLION)
TABLE 344. ISRAEL MALARIA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. ISRAEL MALARIA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 346. ISRAEL MALARIA VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 347. ISRAEL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2030

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Malaria Vaccine market report include:
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech International Limited
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novavax, Inc.
  • BioNTech SE
  • Moderna, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 102.59 Million
Forecasted Market Value ( USD ) by 2030 $ 321.53 Million
Compound Annual Growth Rate25.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Malaria Vaccines - Global Strategic Business Report - Product Image

Malaria Vaccines - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Malaria Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Malaria Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Malaria Vaccines Market Report 2025 - Product Image

Malaria Vaccines Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
India Malaria Vaccine Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

India Malaria Vaccine Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 80 Pages
  • India
From

About the Malaria Vaccine Market

The Malaria Vaccine market is a subset of the larger Vaccines market. It is focused on the development and distribution of vaccines to prevent and treat malaria, a mosquito-borne infectious disease that affects millions of people worldwide. Vaccines are the most effective way to prevent malaria, and the market is driven by the need to reduce the burden of the disease. The Malaria Vaccine market is composed of a variety of stakeholders, including pharmaceutical companies, research institutions, and public health organizations. These stakeholders collaborate to develop and distribute vaccines to those in need. Vaccines are typically administered through injection or oral administration, and are often combined with other preventative measures such as insecticide-treated bed nets and indoor residual spraying. The Malaria Vaccine market is highly competitive, with a number of companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Sanofi, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.